Status: Recruiting
Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
The primary objectives are to determine the recommended Phase 2 dose (RP2D) and optimal treatment regimen, characterize safety and tolerability, and evaluate preliminary efficacy of RYZ401 in subjects with NETs and other selected solid tumors expressing SSTRs.
Participants needed: 104
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: RayzeBio, Inc.Updated: Jun 9, 2026Locations: 9
Eligibility criteria
At least 18 years old at the time of signing the main study informed consent for... [+4]
Prior RPT, including Lu-177. [+7]